Notice bibliographique
Résumé
Letters19 January 2010Red Yeast Rice for Dyslipidemia in Statin-Intolerant PatientsAnna L. Kolpakchi, MD, Ikedieze I. Chukwu, MD, and Maria T. Vlachaki, MD, MBAAnna L. Kolpakchi, MDFrom Baylor College of Medicine and MEDVAMC, Houston, Texas 77030; and British Columbia Cancer Agency, Victoria, British Columbia V8R 6V5, United Kingdom.Search for more papers by this author, Ikedieze I. Chukwu, MDFrom Baylor College of Medicine and MEDVAMC, Houston, Texas 77030; and British Columbia Cancer Agency, Victoria, British Columbia V8R 6V5, United Kingdom.Search for more papers by this author, and Maria T. Vlachaki, MD, MBAFrom Baylor College of Medicine and MEDVAMC, Houston, Texas 77030; and British Columbia Cancer Agency, Victoria, British Columbia V8R 6V5, United Kingdom.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-152-2-201001190-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read with interest the article by Becker and colleagues (1). The emergence of red yeast rice as a dietary supplement and cholesterol-lowering agent shows why such supplements are currently classified as unapproved drugs under the Dietary Supplement Health and Education Act (2).Red yeast rice as a supplement did not exist until 1993. However, it has been used as a food coloring and flavoring agent throughout the Orient for centuries, and its medicinal use for indigestion, diarrhea, and blood circulation is mentioned in ancient Chinese pharmacopoeia. Originally, it was made by fermenting cooked white rice with ...References1. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150:830-9, W147-9. [PMID: 19528562] LinkGoogle Scholar2. Dietary Supplement Health and Education Act of 1994. Pub. L. No. 103-417 (1994). Google Scholar3. Endo A. The origin of the statins. 2004. Atheroscler Suppl. 2004;5:125-30. [PMID: 15531285] CrossrefMedlineGoogle Scholar4. Wang L, Lu Z, Chi J, Wang W, Su M, Kou W, et al. Multicenter clinical trial of the serum lipid-lowering effects of a Monascus purpureus (red yeast) rice preparation from traditional chinese medicine. Curr Ther Res Clin Exp. 1997;58:964-78. CrossrefGoogle Scholar5. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr. 1999;69:231-6. [PMID: 9989685] CrossrefMedlineGoogle Scholar6. U.S. Department of Health and Human Services. Food and Drug Administration. Pharmanex, Inc, administrative proceeding. Pub. Doc. No. 97P-0441. Google Scholar7. Prasad GV, Wong T, Meliton G, Bhaloo S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation. 2002;74:1200-1. [PMID: 12438974] CrossrefMedlineGoogle Scholar8. Smith DJ, Olive KE. Chinese red rice-induced myopathy. South Med J. 2003;96:1265-7. [PMID: 14696880] CrossrefMedlineGoogle Scholar9. Mueller PS. Symptomatic myopathy due to red yeast rice [Letter]. Ann Intern Med. 2006;145:474-5. [PMID: 16983142] LinkGoogle Scholar10. Cartin-Ceba R, Lu LB, Kolpakchi A. A ‘natural’ threat [Letter]. Am J Med. 2007;120:3-4. [PMID: 17976405] CrossrefMedlineGoogle Scholar11. Lapi F, Gallo E, Bernasconi S, Vietri M, Menniti-Ippolito F, Raschetti R, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products [Letter]. Br J Clin Pharmacol. 2008;66:572-4. [PMID: 18637891] CrossrefMedlineGoogle Scholar12. Roselle H, Ekatan A, Tzeng J, Sapienza M, Kocher J. Symptomatic hepatitis associated with the use of herbal red yeast rice [Letter]. Ann Intern Med. 2008;149:516-7. [PMID: 18838736] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Baylor College of Medicine and MEDVAMC, Houston, Texas 77030; and British Columbia Cancer Agency, Victoria, British Columbia V8R 6V5, United Kingdom.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSymptomatic Myopathy due to Red Yeast Rice Paul S. Mueller Symptomatic Hepatitis Associated with the Use of Herbal Red Yeast Rice Harry Roselle , Andrew Ekatan , Jausheng Tzeng , Mark Sapienza , and Jeffrey Kocher Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients David J. Becker , Ram Y. Gordon , Steven C. Halbert , Benjamin French , Patti B. Morris , and Daniel J. Rader Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients David G. Le Couteur Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients Alfredo Vannacci , Francesco Lapi , Eugenia Gallo , Francesca Menniti-Ippolito , Alessandro Mugelli , and Fabio Firenzuoli Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients David J. Becker and Ram Y. Gordon Metrics Cited byStrategies to preserve the use of statins in patients with previous muscular adverse effects 19 January 2010Volume 152, Issue 2Page: 133-134KeywordsConflicts of interestDiarrheaDrug administrationDrugsDyslipidemiaFoodInternetSafetyToxicity ePublished: 19 January 2010 Issue Published: 19 January 2010 Copyright & PermissionsCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,007 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,000 |
| Bibliométrie | 0,001 | 0,001 |
| Études des sciences et des technologies | 0,000 | 0,001 |
| Communication savante | 0,001 | 0,001 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,002 | 0,003 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,011 | 0,003 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».